Open-source approaches for the repurposing of existing or failed candidate drugs: Learning from and applying the lessons across diseases

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 753-766

  Allarakhia, Minna ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Human capacity development; Models of collaboration; Neglected tropical diseases; Open source; Rare diseases; Repurposing

Indexed keywords

AMPHOTERICIN B; ASTEMIZOLE; AVERMECTIN; CHLOROQUINE; EFLORNITHINE; MILTEFOSINE; NEW DRUG; PHOSPHODIESTERASE INHIBITOR; TAMOXIFEN;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; DATA PROCESSING; DRUG DEVELOPMENT; DRUG REDEVELOPMENT; DRUG REPOSITIONING; ELEPHANTIASIS; HUMAN; INFORMATION PROCESSING; LEISHMANIASIS; MALARIA; MODEL; NEGLECTED DISEASE; NONHUMAN; ONCHOCERCIASIS; OPEN SOURCE MODEL; PATENT; PHARMACEUTICS; RARE DISEASE; REVIEW; TECHNOLOGY; TROPICAL DISEASE; TUBERCULOSIS; COOPERATION; ECOSYSTEM; NEGLECTED DISEASES; ORGANIZATION AND MANAGEMENT; TROPICAL MEDICINE;

COOPERATIVE BEHAVIOR; DRUG DISCOVERY; ECOSYSTEM; HUMANS; NEGLECTED DISEASES; PRIVATE SECTOR; PUBLIC SECTOR; TROPICAL MEDICINE;

EID: 84881303961     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S46289     Document Type: Review

References (72)

1. Alison M. NCATS launches drug repurposing program. Nat Biotechnol. 2012;30(7):571-572.
2. National Center for Advancing Translational Sciences. Rescuing and repurposing drugs. Available from: http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/rescue-repurpose.html. Accessed March 21, 2013.
3. Philippidis A. NCATS, MRC take aim at teaching old drug new tricks. 2012. Available from: http://www.genengnews.com/insight-and-intelligenceand153/ncats-mrc-take-aim-at-teaching-old-drugs-new-tricks/77899618. Accessed June 16, 2013.
4. Medical Research Council. Alzheimer's, cancer and rare disease research to benefit from landmark MRC-AstraZeneca compound collaboration [press release]. London: MRC; 2012 [Oct 31]. Available from: http://www.mrc.ac.uk/Newspublications/News/MRC008918. Accessed March 21, 2013.
5. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med. 2011;57(2): 153-160.
6. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417(6684):74-78.
7. Gao Z, Li H, Zhang H, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics. 2008;9:104.
8. Günther S, Kuhn M, Dunkel M, et al. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res. 2008;36(Database issue):D919-D922.
9. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011; 39(Database issue):D1035-D1041.
10. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8): 673-683.
11. Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R. Network analysis of FDA approved drugs and their targets. Mt Sinai J Med. 2007;74(1):27-32.
12. Poh A. Breathing new life into old drugs. 2008. Available from: http://www.bio-itworld.com/issues/2008/nov-dec/chantest.html. Accessed July 19, 2013.
13. Ha S, Seo YJ, Kwon MS, Chang BH, Han CK, Yoon JH. IDMap: facilitating the detection of potential leads with therapeutic targets. Bioinformatics. 2008;24(11):1413-1415.
14. Open PHACTS [website on the Internet]. Available from: http://www.openphacts.org. Accessed March 21, 2013.
15. Wu Z, Wang Y, Chen L. Network-based drug repositioning. Mol Biosyst. 2013;9(6):1268-1281.
16. Emig D, Ivliev A, Pustovalova O, et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS One. 2013;8(4):e60618.
17. von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 2011;39(Database issue): D1060-D1066.
18. Giacomotto J, Ségalat L. High-throughput screening and small animal models, where are we? Br J Pharmacol. 2010;160(2):204-216.
19. National Institutes of Health. NIH and Lilly to generate public resource of approved and investigational medicines [press release]. Bethesda (MD): NIH; 2012 [Mar 13]. Available from: http://www.nih.gov/news/health/mar2012/ncats-13.htm. Accessed March 21, 2013.
20. Thayer AM. Drug repurposing. Chem Eng News. 2012;90(40):15-25.
21. Genetic Engineering and Biotechnology News. Roche, Broad Institute seek new uses for old drugs. 2012. Available from: http://www.genengnews.com/gen-news-highlights/roche-broad-institute-seek-new-uses-for-old-drugs/81247689. Accessed June 16, 2013.
22. Chong CR, Chen X, Shi L, Liu OJ, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006;2(8):415-416.
23. Huang R, Southall N, Wang Y, et al. The NCGC Pharmaceutical Collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011;3(80):80ps16.
24. Muthyala R. Orphan/rare drug discovery through drug repositioning. Drug Discov Today Ther Strateg. 2011;8(3-4):71-76.
25. International Rare Diseases Research Consortium [website on the Internet]. Available from: http://www.irdirc.org. Accessed March 21, 2013.
26. Xu K, Coté TR. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief Bioinform. 2011;12(4):341-345.
27. US Food and Drug Administration. A valuable resource for drug developers: the Rare Disease Repurposing Database (RDRD). 2011. Available from: http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm216147.htm. Accessed March 21, 2013.
28. Marusina K, Welsch DJ, Lynn R, Brock D, Bahr N. The CTSA Pharmaceutical Assets Portal-a public-private partnership model for drug repositioning. Drug Discov Today Ther Strateg. 2011;8(3-4):77-83.
29. World Intellectual Property Organization Re:Search [website on the Internet]. Available from: http://www.wipo.int/research/en. Accessed March 21, 2013.
30. Johns Hopkins Clinical Compound Screening Initiative [website on the Internet]. Available from: http://www.jhccsi.org/background.html. Accessed March 21, 2013.
31. Cures Within Reach [website on the Internet]. Available from: http://www.cureswithinreach.org/about-us. Accessed March 21, 2013.
32. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnerships. Cancer Res. 2012;72(5):1055-1058.
33. Hassig CA, Smith LH, Jackson M. Creating the world's most comprehensive drug repurposing library. 2012. Available from: http://www.americanlaboratory.com/913-Technical-Articles/114059-Creating-the-World-s-Most-Comprehensive-Drug-Repurposing-Library. Accessed June 16, 2013.
34. Arbanas C. Washington University, Pfizer announce groundbreaking research collaboration. 2010. Available from: http://news.wustl.edu/news/Pages/20770.aspx. Accessed June 16, 2013.
35. Boston's Children Hospital. Children's Hospital Boston and Pfizer enter into novel collaborative research agreement for muscular dystrophy therapeutics. 2011. Available from: http://childrenshospital.org/newsroom/Site1339/mainpageS1339P795.html. Accessed June 16, 2013.
36. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008;3:33.
37. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy. 2010;95(2-3):216-228.
38. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov. 2010;9(12):921-929.
39. Peabody JW, Ruby A, Cannon P. The economics of orphan drug policy in the US. Can the legislation be improved? Pharmacoeconomics. 1995;8(5):374-384.
40. Allarakhia M. Evolving concept of openness in the health commons: engaging global stakeholders in technology development for malaria. 2011. Available from: http://www.bioendeavor.net/CommonData/Resources/ECHC.pdf. Accessed March 21, 2013.
41. Agres T. New life for old drugs. 2011. Available from: http://www.dddmag.com/articles/2011/07/new-life-old-drugs. Accessed June 16, 2013.
42. Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg. 2011;8(3-4): 61-69.
43. Muthyala R. Orphan/rare drug discovery through drug repositioning. Drug Discovery Today. 2011; 8(3-4): 71-76.
44. Scott C, Núñez M. Grid computing guiding malaria drug discovery. 2009. Available from: http://www.scidev.net/en/news/grid-computing-guiding-malaria-drug-discovery.html. Accessed June 16, 2013.
45. Indiana University-Purdue University Indianapolis. Molecules made by IUPUI students may have potential to cure diseases. 2011. Available from: http://newscenter.iupui.edu/4997/Molecules-Made-by-IUPUI-Students-May-Have-Potential-To-Cure-Diseases110124. Accessed June 16, 2013.
46. American Type Culture Collection. What we offer. Available from: http://www.atcc.org/About/About_ATCC/What_We_Offer.aspx. Accessed June 16, 2013.
47. Wu Y, Fairfield AS, Oduola A, Cypess RH. The Malaria Research and Reference Reagent Resource (MR4) Center-creating African opportunities. Afr J Med Sci. 2001;30 Suppl:52-54.
48. Allarakhia M, Ajuwon L. Understanding and creating value from open source drug discovery for neglected tropical diseases. Expert Opin Drug Discov. 2012;7(8):643-657.
49. Allarakhia M. Developing a framework for understanding and enabling open source drug discovery. Expert Opin Drug Discov. 2010;5(8): 709-714.
50. Kinnings SL, Liu N, Buchmeier N, Tonge PJ, Xie L, Bourne PE. Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. PLoS Comput Biol. 2009;5:e1000423.
51. Gloeckner C, Garner AL, Mersha F, et al. Repositioning of an existing drug for the neglected tropical disease onchocerciasis. Proc Natl Acad Sci U S A. 2010;107(8):3424-3429.
52. Lim LE, Vilchèze C, Ng C, Jacobs WR Jr, Ramón-García S, Thompson CJ. Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. Antimicrob Agents Chemother. 2013;57(2):1040-1046.
53. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg. 2006;100 Suppl 1:S26-S33.
54. Miguel DC, Yokoyama-Yasunaka JK, Andreoli WK, Mortara RA, Uliana SR. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. J Antimicrob Chemother. 2007;60(3):526-534.
55. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist. 2012;2:11-19.
56. [No authors listed]. One world problem, one world solution? Nature Rev Drug Discov. 2005;4:701.
57. Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG. Drug repositioning for orphan diseases. Brief Bioinform. 2011;12(4): 346-356.
58. Pollastri MP, Campbell RK. Target repurposing for neglected diseases. Future Med Chem. 2011;3(10):1307-1315.
59. Robertson SA, Renslo AR. Drug discovery for neglected tropical diseases at the Sandler Center. Future Med Chem. 2011;3(10):1279-1288.
60. Bhardwaj A, Scaria V, Raghava GP, et al. Open source drug discovery-a new paradigm of collaborative research in tuberculosis drug development. Tuberculosis (Edinb). 2011;91(5):479-486.
61. Open Source Drug Discovery [website on the Internet]. Available from: http://www.osdd.net. Accessed February 15, 2012.
62. Sreelata M. Open source TB megaproject yields first fruits. 2010. Available from: http://www.scidev.net/en/news/open-source-tb-megaproject-yields-first-fruits.html. Accessed June 16, 2013.
63. Nelson R, editor. National Innovation Systems: A Comparative Analysis. Oxford: Oxford University Press; 1993.
64. Freeman C. Technology and Economic Performance: Lessons from Japan. London: Pinter; 1987.
65. Coles LD, Cloyd JC. The role of academic institutions in the development of drugs for rare and neglected diseases. Clin Pharmacol Ther. 2012;92(2):193-202.
66. Ekins S, Williams AJ, Krasowski MD, Freundlich JS. In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today. 2011;16(7-8):298-310.
67. Sardana D, Zhu C, Zhang M, Gudivada RC, Yang L, Jegga AG. Drug repositioning for orphan diseases. Brief Bioinform. 2011;12(4): 346-356.
68. Allarakhia M, Walsh S. Managing knowledge assets under conditions of radical change: The case of the pharmaceutical industry. Technovation. 2011;31(2):105-117.
69. Metcalfe S. The economic foundations of technology policy: equilibrium and evolutionary perspectives. In: Stoneman P, editor. Handbook of the Economics of Innovation and Technological Change. Oxford: Blackwell; 1995.
70. Hess C. Ostrom E. Understanding Knowledge as a Commons: From Theory to Practice. Cambridge (MA): Blackwell; 2006.
71. Organisation for Economic Co-operation and Development. National systems of innovation. 1997. Available from: http://www.oecd.org/science/inno/2101733.pdf. Accessed March 21, 2013.
72. PR Newswire. Transparency Life Sciences launches Indication Finder crowdsourcing tool for drug repurposing. 2012. Available from: http://www.prnewswire.com/news-releases/transparency-life-sciences-launches-indication-finder-crowdsourcing-tool-for-drug-repurposing-175572351.html. Accessed April 2, 2013.